Literature DB >> 12865923

Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines.

O Margalit1, L Eisenbach, N Amariglio, N Kaminski, A Harmelin, R Pfeffer, M Shohat, G Rechavi, R Berger.   

Abstract

Despite advances in the management of solid tumours, the development of metastases continues to be the most significant problem and cause of death for cancer patients. To define genetic determinants of pulmonary metastases, we have applied oligonucleotide microarrays to established murine models of highly metastatic D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. These models are characterised by primary subcutaneous growth in C57BL/6J mice, a period of minimal residual disease and spontaneous pulmonary metastases. Microarray analysis defined seven genes, namely - arginase, brain natriuretic peptide (BNP), interleukin-1 alpha (IL-1 alpha), plasminogen activator inhibitor-2 (PAI-2), surfactant protein C (SP-C), uteroglobin (UG) and wnt-1-induced secreted protein-1 (WISP-1), which were consistently elevated in pulmonary metastases compared to the primary tumour of both D122 and B16-F10.9 models. Previous studies demonstrated that two of these seven genes, IL-1 alpha and PAI-2, are involved in the metastatic process. The results obtained by the microarrays were confirmed by real-time quantitative PCR, for three chosen genes - PAI-2, WISP-1 and UG. Our approach aimed to identify genes essential for the metastatic process in general and for pulmonary metastases specifically. Further research should address the precise role of these genes in the metastasising process to the lungs and test if they could be used as targets for future therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865923      PMCID: PMC2394268          DOI: 10.1038/sj.bjc.6600977

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


A crucial event during cancer progression is the switch from a locally growing tumour to a metastatic one. Tumour development and metastasis are complex processes that include transformation, proliferation, resistance to apoptosis, invasion, neovascularisation and metastatic spread (Liotta ). Studies to identify molecules involved in tumour development and progression have resulted in the identification of a number of individual candidates that function as cell growth factors (Grandis ), adhesion molecules (Van Waes , 1995), proteases (Andreasen ), and cytokines that promote inflammation and angiogenesis (Chen , 1999). The discovery of these molecules may be useful in developing new therapeutic interventions. For instance, synthetic Arg-Gly-Asp (RGD) containing peptides can disrupt integrin function (e.g., vitronectin receptor) and successfully inhibit both in vitro and in vivo melanoma cell invasion (Gehlsen ). Metastasis is a multiple-step process in which cancer cells leave the primary tumour site and relocate in a remote organ. This process involves interactions between cancer cells and their surrounding microenvironment. Tumours that metastasise do so to preferred target organs. To explain this apparent specificity, over 100 years ago, Paget formulated his ‘seed and soil’ hypothesis; that is, cells from a given tumour would ‘seed’ only favourable ‘soil’ in a target organ, one that supports colonisation for metastasis to occur. Several studies used an in vivo selection scheme to select highly metastatic cell lines (Clark ; Chen ; Khanna ). By analysing these cells on microarrays, gene expression patterns that correlate with progression to a metastatic phenotype have been defined. Clark have shown that the small GTPase RhoC enhances metastasis when overexpressed, whereas a dominant-negative Rho inhibits metastasis. Analysis of the phenotype of cells expressing dominant-negative Rho or RhoC indicates that RhoC is important in tumour cell invasion. The process of selecting highly metastatic cell lines, as done by Clark , resulted in a large number of genes related solely to metastasis, but not to the microenvironmental changes in the preferred target organs. To provide insight into mechanisms that allow tumours to metastasise specifically to the lungs, we searched for the genes coordinately overexpressed in pulmonary metastases of two distinct metastatic cell lines of different embryonic origin. The cell lines we used were the highly metastatic mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma. We hypothesised that genes overexpressed in pulmonary metastases of both cell lines, might play a key role in both metastasis and homing of the metastasising cells, specifically to the lungs.

MATERIALS AND METHODS

Mice and cell cultures

Ten inbred male and female C57BL/6J mice, 12 weeks old, were grown and maintained in the animal facilities of the Weizmann Institute of Science and Tel-Aviv University. All animal experiments have been carried out with ethical committee approval. The ethical guidelines that were followed meet the standards required by the UKCCCR guidelines (Workman ). The highly metastatic D122 clone of the C57BL/6-derived Lewis lung carcinoma (Eisenbach ) was maintained in DMEM supplemented with 10% heat-inactivated fetal calf serum, glutamine, combined antibiotics, sodium pyruvate and nonessential amino acids. The highly metastatic B16-F10.9 clone of the C57BL/6-derived malignant melanoma (Porgador ) was grown in DMEM supplemented with 10% heat-inactivated fetal calf serum, glutamine and combined antibiotics. The mice were divided into four groups. Groups 1 and 2, consisting of three mice each, male and female, respectively, were injected intra-footpad with 2 × 105 D122 or B16-F10.9 cells/mouse, respectively. Groups 3 and 4, consisting of two mice each, male and female, respectively, served as a control. After 5 weeks, when primary tumours reached ∼0.8 cm in diameter, animals were anaesthetized and tumours were dissected and stored at −80°C. After an additional 4 weeks, lungs containing pulmonary metastases were dissected. The lungs of the mice in the control groups were dissected at the matching age. All specimens were snap-frozen in liquid nitrogen.

Preparation of labelled cRNA

Probe preparation was performed as recommended by the manufacturer of the microarrays (). Briefly, total RNA was isolated from pooled primary tumours and pooled lungs by homogenisation in ice-cold Trizol (Invitrogen). The RNA was then used as template for double-stranded cDNA synthesis with an oligo(dT)24 primer containing a T7 RNA polymerase promoter site added to the 3′ end (Genset, La Jolla, CA, USA). The cDNA was extracted with phenol/chloroform, ethanol-precipitated, and used as a template for in vitro transcription (Ambion T7 Megascript system) with biotin-labelled nucleotides (Enzo Diagnostics). Labelled cRNA was fragmented and a hybridisation mix was generated as recommended ().

Hybridisation of microarrays

Aliquots of each sample (10 μg cRNA in 200 μl hybridisation mix) were hybridised to a Genechip Hugene FL array. After hybridisation, each array was washed, stained with streptavidin phycoerythrin (Molecular Probes), washed again, hybridised with biotin labelled antistreptavidin phycoerythrin antibodies, restained with streptavidin phycoerythrin (Molecular Probes), and scanned (Hewlett-Packard, GeneArray scanner G2500A).

Analysis of Genechip data

Scanned output files were visually inspected for hybridisation artefacts and then analysed using Genechip® 4.0 software (Affymetrix). Arrays were scaled to an average intensity of 600 per gene and analysed independently. The expression value for each gene was determined by calculating the average of differences (perfect match intensity minus mismatch intensity) of the probe pairs in use for this gene. The expression analysis files created by Genechip® 4.0 software were then transferred to a database (Microsoft Access) linked to Internet genome databases (e.g. NHLBI, Swiss Prot and GeneCards) to update gene definitions. A value of 20 was assigned to all measurements lower than 20. We did not include in the analysis genes that did not have at least one average difference intensity value ⩾100 which was defined as ‘present’ call by Affymetrix criteria. For cluster analysis, we used CLUSTER and TREEVIEW programs described by Eisen . Fold ratios were calculated for each primary tumour against the pulmonary metastases of the same model and for the pulmonary metastases against the normal lung of the same gender. To ensure that the enhanced expression of genes in the pulmonary metastases was not due solely to the influence of the microenvironment, we removed genes with a higher level of expression in the normal murine lung compared to the pulmonary metastases. This criterion filtered 55, 78 and 91% of the genes that were otherwise considered as overexpressed in the D122, B16-F10.9 and both models, respectively.

Real-time quantitative PCR analysis

Relative quantitative PCR was performed using the LightCycler System® (Roche Diagnostics). An aliquot of 6 μg of the previously extracted total RNA was reverse transcribed using Moloney Murine Leukemia Virus-Reverse Transcriptase (RT) and random hexamers as primer (Promega). The obtained cDNA was diluted 1/10 with water and 5 μl was used for amplification. The PCR was performed with the LightCycler FastStart DNA SYBR GreenI Kit (Roche Diagnostics) according to the protocol provided in the kit. To control for specificity of the amplification products, a melting curve analysis was performed. No amplification of unspecific products was observed. In addition, PCR products were gel separated to confirm a band of the expected size. The relative initial amount of cDNA of a particular template in the cDNA mixture was extrapolated from a standard curve. The standards, composed of five serial dilutions of one of the cDNAs, ranging from 1/5 to 1/1000 of the original cDNA, were run in parallel with the samples under identical PCR conditions, amplified with the same set of primers. The slope of the standard curve was converted to the amplification efficiency E by the following algorithm: E=10−1/. The primers used for all four genes – PAI-2, RhoC, WISP-1 and UG had an efficiency >1.85 (data not shown). The relative amounts obtained were normalised by the housekeeping gene beta-actin, whose levels of expression were not changed significantly according to the microarrays (data not shown). The detailed procedure for quantification has been described by Ginzinger (2002). The primer sequences were (5′ to 3′): beta-actin – CTGAGAGGGAAATCGTGCG, GGTGGTACCACCAGACAAC; PAI-2 – CTGCTACCCGAAGGTTCTG, GGAAGCAACAGGAGCATGC; RhoC – GCTGGGCAAGAAGACTACG, CCTTCCTCAGATCGAACCG; WISP-1 – CGTGGAGCAACGGTATGAG, GAGAGTGAAGTTCGTGGCC; UG – CATGCTGTCCATCTGCTGC, CTCTTGTGGGAGGGTATCC.

RESULTS

Global analysis of gene expression

Global analysis of gene expression reveals a correlation between the primary tumour of each model, D122 or B16-F10.9, to its matching pulmonary metastases. In other words, as expected, the diversity between the two models is greater than the diversity between the primary tumour and the pulmonary metastases of the same model. Only genes with at least one average difference intensity value ⩾100, which are defined as ‘present’ by Affymetrix criteria, were included in the cluster analysis (Figure 1).
Figure 1

Dendrogram of cluster analysis of microarrays. CL, normal male murine lung – Control for the D122 Lewis lung model; CM, normal female murine lung – control for the B16-F10.9 melanoma model; ML – pulmonary metastases of the D122 Lewis lung model; PL – primary tumour of the D122 Lewis lung model; MM – pulmonary metastases of the B16-F10.9 melanoma model; PM – primary tumour of the B 16-F10.9 melanoma model.

Dendrogram of cluster analysis of microarrays. CL, normal male murine lung – Control for the D122 Lewis lung model; CM, normal female murine lung – control for the B16-F10.9 melanoma model; ML – pulmonary metastases of the D122 Lewis lung model; PL – primary tumour of the D122 Lewis lung model; MM – pulmonary metastases of the B16-F10.9 melanoma model; PM – primary tumour of the B 16-F10.9 melanoma model.

Oligonucleotide microarray analysis

The tumour model described above was used with the highly metastatic mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Microarray experiments examined differences in gene expressions between the subcutaneous primary tumour and the pulmonary metastases. We focus on the genes that were overexpressed in the pulmonary metastases compared to the primary tumour, since we assume that transcripts overexpressed in metastatic tissue have applicable diagnostic and therapeutic potential. Forty-two and 16 genes were overexpressed in pulmonary metastases derived from the mouse D122 and B16-F10.9 cell lines, respectively (Tables 1a and b ). Seven genes, namely – arginase, brain natriuretic peptide (BNP), interleukin-1 alpha (IL-1 alpha), plasminogen activator inhibitor-2 (PAI-2), surfactant protein C (SP-C), uteroglobin (UG) and wnt-1-induced secreted protein-1 (WISP-1), were overexpressed in pulmonary metastases of both cell lines (Table 2 ).
Table 1

Functional groups of genes that were overexpressed, at a fold ⩾2.5, in pulmonary metastases compared to primary tumour in the (a) D122 model and (b) B16-F10.9 model

DescriptionGenBank accession #Fold ratio
(a) D122 model
Apoptosis  
Caspase 3aU548032.9
miap-3U889903.0
MIHAU368427.1
   
Cell adhesion  
Integrin alpha V (Cd51)aU141352.9
IslrAB0245385.2
Lymphocyte antigen 84aY075192.6
   
Cellular matrix  
Actin, alpha 1M123475.5
histone H2a(A)-613, H2a(B)-613 and H2b-613 (H2b)U626734.1
   
Differentiation  
H19X581963.0
Madr2U605302.7
   
ECM/angiogenesis  
Collagen type VI, alpha 3 subunitAF0647499.7
EnamelinU8269810.1
FibronectinM181944.5
Matrilin-2 precursoraU692624.0
Procollagen type X, alpha 1X673483.8
   
Membrane and nuclear membrane  
YE1/48M257753.1
   
Metabolism  
Acetyl coenzyme A dehydrogenase, long-chainaU214892.6
AKR1C13AB0271259.7
FerrochelataseM612153.0
griPGHSaM882426.3
PexU756464.4
   
Receptors/ligands  
Bacteria binding macrophage receptor MARCOU184247.4
GRIP1U390606.4
MIP2X537987.9
   
Signal transduction  
Mess1aU2872614.5
MPAX606642.5
WSB-2AF0331882.6
   
Transcription  
mafFaAB00969410.9
Slug, chicken homologueU795502.5
zinc finger gene OZFaAJ2247635.8
   
Translation  
N-myristoyltransferase 2aAF04332710.8
Ribosomal protein (Rpl12)L042802.8
   
Other  
Dnmt2aAF0121292.8
homer-2aAF0932593.7
Lysophospholipase IU8935210.4
Modifier 2 proteinaX566832.5
P35BaX536192.6
PLA2M723942.6
Retinaldehyde-binding proteinAF0846424.9
SCID complementing gene 2aD781883.6
Sfrp2U885676.8
Synaptobrevin-like proteinX967373.1
   
(b) B16-F10.9 model
Apoptosis  
P53-variantbU597583.9
   
ECM/angiogenesis  
Hyaluronidase 1AF0115675.8
MinopontinX139868.7
VEGF-CU736204.6
   
Metabolism/proteosome  
beta-TrCP protein E3RS Ikappa BbAF0999327.9
Ceramide glucosyltransferaseD8986615.0
   
Signal transduction  
cAMP-dependent Rap 1AF1154806.3
LIM and SH3 protein 1U588825.2
RAB7, member RAS oncogene famillyY133612.8
   
Receptors/ligands  
Mouse homologue of human ocular albinism 1X983522.7
   
Transcription/translation  
Cyclin T1bAF0956403.5
Myeloblastosis oncogene-like 1L352612.9
Zinc-finger protein 40D106325.1
   
Other  
HSP-105L404062.5
Mouse Ig kappa chain V-regionM1823716.5
Potassium channel alpha subunitbAF0085742.9

Indicates genes that were underexpressed in the B16-F10.9 model.

Indicates genes that were underexpressed in the D122 model. Genes that were overexpressed in both models are not shown.

Table 2

Genes that were overexpressed, at a fold ⩾2.5, in pulmonary metastases compared to primary tumour in both D122 and B16-F10.9 models

 GenBank accession #Fold ratio
Description D122 modelF10.9 model
ArginaseU5180522.54.9
BNPD164972.72.7
IL-1 alphaM146393.17.9
PAI-2X164904.42.5
SP-CAA921489239.3102.5
UGL04503383.627.7
WISP-1AF1007773.74.5
Indicates genes that were underexpressed in the B16-F10.9 model. Indicates genes that were underexpressed in the D122 model. Genes that were overexpressed in both models are not shown. We could not detect any consistent difference in the expression of RhoC in pulmonary metastases compared to the primary tumour. As this gene has been previously shown to be important in the metastatic phenotype of melanoma cell lines (Clark ), we confirmed this microarray result using real-time quantitative PCR (RTQ–PCR) (Figure 2).
Figure 2

Comparative ratio analysis by RTQ–PCR and microarrays. Fold ratios were calculated for each primary tumour against the pulmonary metastases. RTQ–PCR results (mean±s.d.) were obtained from three independent experiments, each in duplicate.

Comparative ratio analysis by RTQ–PCR and microarrays. Fold ratios were calculated for each primary tumour against the pulmonary metastases. RTQ–PCR results (mean±s.d.) were obtained from three independent experiments, each in duplicate.

RTQ–PCR confirms overexpression of PAI-2, WISP-1 and UG in pulmonary metastases of both cell lines

To further investigate the reliability of our array data, we measured the expression levels of PAI-2, WISP-1 and UG that were overexpressed in both models using the LightCycler System® (Roche Diagnostics). The expression levels of PAI-2, WISP-1 and UG measured by RTQ–PCR were similar to those measured by the microarrays (Figure 3, UG data not shown).
Figure 3

Comparative ratio analysis by RTQ–PCR and microarrays. Fold ratios were calculated for each primary tumour against the pulmonary metastases. RTQ–PCR results (mean±s.d.) for WISP-1 and PAI-2 were obtained from three and four independent experiments, respectively, each in duplicate (PAI-2 results are illustrated by two representative experiments).

Comparative ratio analysis by RTQ–PCR and microarrays. Fold ratios were calculated for each primary tumour against the pulmonary metastases. RTQ–PCR results (mean±s.d.) for WISP-1 and PAI-2 were obtained from three and four independent experiments, respectively, each in duplicate (PAI-2 results are illustrated by two representative experiments).

DISCUSSION

Previous studies provided insight into the patterns of gene expression that allow tumours to metastasise by comparing highly metastatic vs low metastatic cell lines. This approach identified genes that were overexpressed within the highly metastatic cell line and that were, in general, essential to the nonmetastatic/metastatic switch. One study using this approach demonstrated that the small GTPase RhoC was essential for the enhancement of melanoma metastasis when overexpressed. Furthermore, analysis of the phenotype of melanoma cells expressing dominant-negative Rho or RhoC indicated that RhoC is important in tumour cell invasion (Clark ). In this study, we could identify essential targets expressed within the tumour cell, as a result of interactions with the surrounding microenvironment. The reason for this is the comparison made between two phases of a tumour progression in vivo – the primary site and the metastases, both with the surrounding tissue, originating from a highly metastatic cell line. Our attitude aimed to emphasise genes that could be essential for metastasis to the lungs and might play a key role in homing the tumour cells specifically to that organ. Therefore, in our study, the small GTPase RhoC was not overexpressed in the pulmonary metastases compared to the primary tumour of both cell lines. We therefore argue that RhoC has general importance in tumour invasiveness and in the nonmetatstatic/metastatic switch, but not in the specific metastatic homing to the lungs. Previously, Gemma compared the expression profiles of two subpopulations of an adenocarcinoma cell line with high metastatic potential – PC9/f9 and PC9/f14 – with the parent cell line PC9 using cDNA array. They have shown that the expression of matrix metalloproteinase-2 (MMP-2), plasminogen activator inhibitor-1 (PAI-1) and IL-1 alpha was overexpressed in the highly metastatic subpopulations. There is already abundant experimental evidence that the plasminogen activator system plays a key role in tumour invasion and metastasis (Andreasen ; Schmitt ). A critical balance of uPA, its cell surface receptor uPA-R (CD 87), and its inhibitor PAI-1 is the prerequisite for efficient focal proteolysis, adhesion and migration, and hence, subsequent tumour cell invasion and metastasis. There is evidence that PAI-2 may block uPA-mediated proteolysis and is inversely correlated with tumour progression of nonsmall cell lung carcinomas and neuroendocrine lung tumours (Robert ) and breast cancer (Borstnar ). In contrast, higher expression levels of PAI-2 were found in tumour tissues as compared to their normal equivalents and significant relations were found between PAI-2 and pathological stage in nonsmall cell lung cancer patients (Salden ). Our data suggest a key role for PAI-2 in lung metastasis from different tumour origins. Wnt-1-induced secreted protein (WISP-1) was identified by Pennica as an oncogene regulated by the Wnt-1-beta-catenin pathway and is a member of the CCN family of growth factors, which are cysteine-rich, heparin-binding, secreted proteins associated with the extracellular matrix, and can interact with cellular integrins. Xu identified WISP-1 as beta-catenin-regulated and its forced overexpression in normal rat kidney fibroblasts (NRK-49F) was sufficient to induce their transformation. Recently, it was shown that WISP-1 can both activate the anti-apoptotic Akt/PKB signalling pathway and act to block cell death in the p53-mediated apoptosis pathway (Su ). Wnt-1-induced secreted protein-1 was overexpressed (2 to >25-fold) in 84% of human colon tumours examined compared with patient-matched normal adjacent mucosa (Pennica ). The expression levels of WISP-1, in mammary tumours from Wnt-1 transgenic mice, were high in stromal fibroblasts lying within the fibrovascular tumour stroma, but low focally within tumour cells (Pennica ). Elevated levels of WISP-1 in primary breast cancer were associated with more advanced features, such as tumour size and metastases to axillary lymph nodes (Xie ). In contrast, WISP-1 was found to be one of the 70 prognostic reporter genes able to identify clinical outcome in primary breast cancer patients. It was shown that WISP-1 was overexpressed in the good prognosis group of patients, who did not develop distant metastases within 5 years (Van't Veer ). Furthermore, the mouse WISP-1 is identical to the gene identified as ELM1 (GenBank accession# AB004873). ELM1 is expressed in low, but not high, metastatic mouse melanoma cells, and suppresses the in vivo growth and metastatic potential of K-1735 mouse melanoma cells (Hashimoto ). The contradiction between the above findings may be explained in view of previous studies suggesting that the effect of a single gene may differ according to the genetic and cellular context. For example, c-MYC can induce both cell proliferation and apoptosis (Evan ; Jain ; Pelengaris et al, 2002). Another example was given by Serrano , who showed that the oncogene ras, known for its ability to transform immortal rodent cells to a tumourigenic state, can provoke premature cell senescence in primary human and rodent cells. Here we have demonstrated overexpression of WISP-1 in pulmonary metastases of two distinct metastatic cell lines. We propose a key role for WISP-1 in the metastasising process to the lungs. Interleukin-1 alpha was shown to enhance the adhesion of A549 lung carcinoma and M6 melanoma cells to the vascular surface both in vitro and in vivo, suggesting that IL-1 proteins facilitate the metastatic process (Lauri ). Significant correlation between expression of IL-1 alpha and liver metastasis in gastric carcinoma was shown (Tomimatsu ), suggesting that IL-1 alpha functions universally in the metastatic process. Here we have demonstrated overexpression of IL-1 alpha in pulmonary metastases of two distinct metastatic cell lines. Arginase converts L-arginine to L-ornithine, which is the precursor of polyamines that are essential components of cell proliferation. N-hydroxy-L-arginine (NOHA), a stable intermediate product formed during conversion of L-arginine to NO by nitric oxide synthase, inhibited proliferation of the high arginase-expressing MDA-MB-468 cells, activated caspase-3 and induced apoptosis after 48 h (Singh ). Additionally, Chang have shown that arginase induction in macrophages can enhance tumour cell growth by providing them with polyamines and suppress tumour cytotoxicity by reducing NO production. The arginase inhibitor L-norvaline downregulated this proliferative effect. Yet, an active subunit of arginase was found to inhibit differentially poorly liver metastasizing cell lines (Cavanaugh and Nicolson, 2000). Highly metastatic cells displayed no ability to preferentially inactivate or inhibit the activity of arginase, but they did display slightly greater amounts of intracellular arginine. Here, however, arginase was overexpressed in pulmonary metastases of two distinct metastatic cell lines. Therefore, arginase may be essential for tumour metastasis to the lungs, but not to the liver, and lung macrophages might take part in that process. Brain natriuretic peptide (BNP) is a polypeptide hormone, demonstrated mainly in the heart, which causes vasodilation and natriuresis in man and animals. Elevated levels of BNP are usually associated with cardiac dysfunction (Cowie and Mendez, 2002). There is also evidence that human small cell lung cancer cell lines produce BNP (Ohsaki ). There is no known connection of BNP to tumourigenesis or metastasis. Uteroglobin (UG) was found to be infrequently expressed in non-small cell lung cancer cell lines, despite being abundantly produced by progenitor cells for normal and neoplastic airway epithelium. A549 cells transfected with UG demonstrated a marked reduction in invasiveness and decreased adhesiveness to fibronectin compared with the controls (Szabo ). Surfactant-C (SP-C) is overexpressed in normal lungs and plays an important role in its functioning. Our data show overexpression of UG and SP-C in pulmonary metastases compared to both primary tumours and normal lung. Nevertheless, these genes were also overexpressed in the normal lung compared to the primary tumour. Most of the previously described genetic alterations in various cancers involve inactivation of tumour suppressor genes. The proteins produced from these genes are difficult to target with drugs, because they are inactive or absent in the cancer cells. In contrast, enzymes whose expression is elevated in cancer cells like those encoded by WISP-1, arginase, IL-1 alpha and PAI-2 provide excellent targets for drug discovery purposes. Further research should address the specific role of these genes in the formation of pulmonary metastases from different tumours.
  40 in total

Review 1.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

3.  Genomic analysis of metastasis reveals an essential role for RhoC.

Authors:  E A Clark; T R Golub; E S Lander; R O Hynes
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

4.  Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line.

Authors:  A Gemma; K Takenaka; Y Hosoya; K Matuda; M Seike; F Kurimoto; Y Ono; K Uematsu; Y Takeda; S Hibino; A Yoshimura; M Shibuya; S Kudoh
Journal:  Eur J Cancer       Date:  2001-08       Impact factor: 9.162

5.  Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.

Authors:  R Singh; S Pervin; A Karimi; S Cederbaum; G Chaudhuri
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

6.  Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma.

Authors:  S Tomimatsu; T Ichikura; H Mochizuki
Journal:  Cancer       Date:  2001-04-01       Impact factor: 6.860

7.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).

Authors: 
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

9.  Increase in suprabasilar integrin adhesion molecule expression in human epidermal neoplasms accompanies increased proliferation occurring with immortalization and tumor progression.

Authors:  C Van Waes; D M Surh; Z Chen; M Kirby; J S Rhim; R Brager; R B Sessions; J Poore; G T Wolf; T E Carey
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

10.  Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides.

Authors:  K R Gehlsen; W S Argraves; M D Pierschbacher; E Ruoslahti
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539

View more
  17 in total

1.  A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.

Authors:  Yogesh M Kulkarni; Emily Chambers; A J Robert McGray; Jason S Ware; Jonathan L Bramson; David J Klinke
Journal:  Integr Biol (Camb)       Date:  2012-07-09       Impact factor: 2.192

Review 2.  Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch.

Authors:  Jianghui Meng; Weiwei Chen; Jiafu Wang
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

3.  Abnormal gene expression and gene fusion in lung adenocarcinoma with high-throughput RNA sequencing.

Authors:  Z-H Yang; R Zheng; Y Gao; Q Zhang; H Zhang
Journal:  Cancer Gene Ther       Date:  2014-02-07       Impact factor: 5.987

4.  WNT1-inducible signaling pathway protein-1 contributes to tumor progression and treatment failure in oral squamous cell carcinoma.

Authors:  Eun Kyung Jung; Sun-Ae Kim; Tae Mi Yoon; Kyung-Hwa Lee; Hee Kyung Kim; Dong Hoon Lee; Joon Kyoo Lee; Ik-Joo Chung; Young-Eun Joo; Sang Chul Lim
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

5.  Vessel microport technique for applications in cerebrovascular research.

Authors:  Lei Chen; Karin R Swartz; Michal Toborek
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

6.  Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.

Authors:  H Fukuda; S Mochizuki; H Abe; H J Okano; C Hara-Miyauchi; H Okano; N Yamaguchi; M Nakayama; J D'Armiento; Y Okada
Journal:  Br J Cancer       Date:  2011-10-20       Impact factor: 7.640

7.  WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer.

Authors:  Kun-Chun Chiang; Chun-Nan Yeh; Li-Chuan Chung; Tsui-Hsia Feng; Chi-Chin Sun; Miin-Fu Chen; Yi-Yin Jan; Ta-Sen Yeh; Shin-Cheh Chen; Horng-Heng Juang
Journal:  Sci Rep       Date:  2015-03-03       Impact factor: 4.379

8.  Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer.

Authors:  Ping-Ping Chen; Wen-Jie Li; Yan Wang; Song Zhao; De-Yun Li; Li-Yun Feng; Xiang-Lin Shi; H Phillip Koeffler; Xiang-Jun Tong; Dong Xie
Journal:  PLoS One       Date:  2007-06-20       Impact factor: 3.240

9.  Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.

Authors:  Randal J Westrick; Lisa Payne Røjkjaer; Angela Y Yang; Michael H Roh; Amy E Siebert; David Ginsburg
Journal:  J Thromb Haemost       Date:  2020-10-01       Impact factor: 16.036

10.  WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone.

Authors:  Mitsuaki Ono; Colette A Inkson; Robert Sonn; Tina M Kilts; Luis F de Castro; Azusa Maeda; Larry W Fisher; Pamela G Robey; Agnes D Berendsen; Li Li; Nancy McCartney-Francis; Aaron C Brown; Nigel P S Crawford; Alfredo Molinolo; Alka Jain; Neal S Fedarko; Marian F Young
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.